BioXcel Therapeutics (BTAI) Revenue & Revenue Breakdown
BioXcel Therapeutics Revenue Highlights
Latest Revenue (Y)
$1.38M
Latest Revenue (Q)
$1.10M
BioXcel Therapeutics Revenue by Period
BioXcel Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $1.38M | 268.00% |
| 2022-12-31 | $375.00K | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2016-12-31 | - | - |
BioXcel Therapeutics generated $1.38M in revenue during NA 2023, up 268.00% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
BioXcel Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $1.10M | 89.69% |
| 2024-03-31 | $582.00K | 54.79% |
| 2023-12-31 | $376.00K | 10.26% |
| 2023-09-30 | $341.00K | -25.38% |
| 2023-06-30 | $457.00K | 121.84% |
| 2023-03-31 | $206.00K | -13.45% |
| 2022-12-31 | $238.00K | 73.72% |
| 2022-09-30 | $137.00K | 100.00% |
| 2022-06-30 | - | 100.00% |
| 2022-03-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2021-09-30 | - | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2021-03-31 | - | -100.00% |
| 2020-12-31 | $0.02 | 100.00% |
| 2020-09-30 | $0.01 | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2019-09-30 | - | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2018-09-30 | - | 100.00% |
| 2018-06-30 | - | 100.00% |
| 2018-03-31 | - | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2017-09-30 | - | 100.00% |
| 2017-06-30 | - | 100.00% |
| 2017-03-31 | - | - |
BioXcel Therapeutics generated $1.10M in revenue during Q2 2024, up 89.69% compared to the previous quarter, and up 535.92% compared to the same period a year ago.
BioXcel Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| EXEL | Exelixis | $1.83B | $637.18M |
| AMLX | Amylyx Pharmaceuticals | $380.79M | $88.64M |
| APLS | Apellis Pharmaceuticals | $366.28M | $179.14M |
| TGTX | TG Therapeutics | $233.66M | $73.47M |
| MREO | Mereo BioPharma Group | $10.00M | - |
| BTAI | BioXcel Therapeutics | $1.38M | $1.10M |
| XFOR | X4 Pharmaceuticals | - | $563.00K |
| VKTX | Viking Therapeutics | - | - |
| DAWN | Day One Biopharmaceuticals | - | $8.19M |
| ABOS | Acumen Pharmaceuticals | - | - |
| INZY | Inozyme Pharma | - | - |
| ELEV | Elevation Oncology | - | - |
| MDGL | Madrigal Pharmaceuticals | - | - |
| TERN | Terns Pharmaceuticals | - | - |
| HEPA | Hepion Pharmaceuticals | - | - |
| EFTR | eFFECTOR Therapeutics | - | - |
BTAI Revenue FAQ
What is BioXcel Therapeutics’s yearly revenue?
BioXcel Therapeutics's yearly revenue for 2023 was $1.38M, representing an increase of 268.00% compared to 2022. The company's yearly revenue for 2022 was $375K, representing an increase of 100.00% compared to 2021. BTAI's yearly revenue for 2021 was $0, representing an increase of 100.00% compared to 2020.
What is BioXcel Therapeutics’s quarterly revenue?
BioXcel Therapeutics's quarterly revenue for Q2 2024 was $1.1M, a 89.69% increase from the previous quarter (Q1 2024), and a 141.58% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $582K, a 54.79% increase from the previous quarter (Q4 2023), and a 182.52% increase year-over-year (Q1 2023). BTAI's quarterly revenue for Q4 2023 was $376K, a 10.26% increase from the previous quarter (Q3 2023), and a 57.98% increase year-over-year (Q4 2022).
What is BioXcel Therapeutics’s revenue growth rate?
BioXcel Therapeutics's revenue growth rate for the last 3 years (2021-2023) was 0%, and for the last 5 years (2019-2023) was 0%.